Arcutis Raises 2026 Sales Guidance on ZORYVE Growth
Arcutis Biotherapeutics reported third quarter 2026 results, with ZORYVE net product revenue rising 45% year over year.
Updated on Nov. 4, 2026 in Corporate Finance
Arcutis Biotherapeutics reported third quarter 2026 financial results, with ZORYVE net product revenue of $143.9 million, up 45% versus Q3 2025 and 11% versus Q2 2026. The company also raised its full-year 2026 net product sales guidance to $535 million-$545 million.
Why it matters
The revenue growth and raised guidance signal sustained demand for ZORYVE and a stronger financial position for the company, which reported net income of $8.8 million for the quarter. Investors and California-based observers can track the company's progress as it advances its pipeline and commercial strategy.
Arcutis reported Q3 2026 net cash from operating activities of $18.9 million and SG&A expenses of $99.6 million, with R&D expenses of $22.4 million. The company ended the quarter with $259.8 million in cash and marketable securities, though future operating results remain subject to the timing of its commercial and development programs.
The players
Arcutis Biotherapeutics
Arcutis Biotherapeutics is a Westlake Village, California-based biopharmaceutical company focused on dermatology treatments, including the ZORYVE product line.
Simone Biles
Simone Biles is an Olympic gymnast and public figure who partnered with Arcutis to launch the Skin to Believe In awareness campaign.
Rob Lisicki
Rob Lisicki is an executive who was appointed chief commercial officer of Arcutis Biotherapeutics, effective November 4, 2026.
The details
Revenue growth was driven by higher unit demand and modest improvements in gross-to-net deductions, while SG&A rose on greater marketing spend for the Skin to Believe In campaign launched with Simone Biles and expanded sales personnel. Arcutis also initiated a pivotal Phase 3 trial of ZORYVE cream 0.3% for moderate to severe atopic dermatitis.
Timeline
- September 30, 2026: Third quarter ended.
- October 2026: Rob Scott, MD, appointed to the Board of Directors.
- November 4, 2026: Financial results announced and Rob Lisicki appointed chief commercial officer, effective that date.
- February 23, 2027: FDA target action date for the ZORYVE cream 0.05% infant indication.
- Q1 2027: Expected FDA decision on the infant indication and results for ZORYVE foam 0.3% in hidradenitis suppurativa.
Market Landscape
Arcutis's revenue growth places it among companies expanding topical dermatology products into broader patient populations, including the pending FDA review of a ZORYVE indication for infants as young as 3 months. The company's pipeline extends into vitiligo and hidradenitis suppurativa, reflecting a strategy of widening its dermatology footprint beyond atopic dermatitis.
For shareholders, the raised 2026 guidance and positive quarterly net income provide a concrete benchmark for evaluating the company's commercial execution. Investors tracking the stock can weigh the $259.8 million cash position against the pending regulatory and clinical milestones scheduled for early 2027.
The takeaway
Revenue growth and a raised full-year outlook suggest the company's commercial strategy is gaining traction. Readers tracking the company should watch the early 2027 FDA decision and clinical updates for signs of how the pipeline is progressing.
What happens next
The FDA's target action date for the ZORYVE cream 0.05% infant indication is February 23, 2027, and Arcutis expects to report hidradenitis suppurativa results and a program advancement decision in Q1 2027.
Further reading
Explore more on Corporate Finance developments across California.
Source note: This article includes information reported by The Manila times.
